Listed

Psyence Biomedical LTD.

PBMNasdaqCIK 1985062HealthcareFiscal year ends Mar 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Balance sheet

Cash and equivalents$6.1m, FY2025
Shareholders' equity$6.7m, FY2025
Line itemUnitperiod not labelled2022-03-31period not labelled2023-03-31FY20242024-03-31FY20252025-03-31
Cash and equivalents$m1.8Cash and equivalents, period not labelled, at 2022-03-31$1.8m. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure1.3Cash and equivalents, period not labelled, at 2023-03-31$1.3m. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure0.7Cash and equivalents, FY2024, at 2024-03-31$733.2k. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure6.1Cash and equivalents, FY2025, at 2025-03-31$6.1m. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure
Current assets$m1.8Current assets, period not labelled, at 2022-03-31$1.8m. XBRL concept ifrs-full:CurrentAssets. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure1.6Current assets, period not labelled, at 2023-03-31$1.6m. XBRL concept ifrs-full:CurrentAssets. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure1.1Current assets, FY2024, at 2024-03-31$1.1m. XBRL concept ifrs-full:CurrentAssets. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure6.6Current assets, FY2025, at 2025-03-31$6.6m. XBRL concept ifrs-full:CurrentAssets. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure
Total assets$m1.8Total assets, period not labelled, at 2022-03-31$1.8m. XBRL concept ifrs-full:Assets. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure1.6Total assets, period not labelled, at 2023-03-31$1.6m. XBRL concept ifrs-full:Assets. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure1.1Total assets, FY2024, at 2024-03-31$1.1m. XBRL concept ifrs-full:Assets. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure7.3Total assets, FY2025, at 2025-03-31$7.3m. XBRL concept ifrs-full:Assets. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure
Total liabilities$m0.1Total liabilities, period not labelled, at 2022-03-31$131.6k. XBRL concept ifrs-full:Liabilities. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure1.8Total liabilities, period not labelled, at 2023-03-31$1.8m. XBRL concept ifrs-full:Liabilities. 20-F filed 2024-07-29, accession 0001410578-24-001112.Report this figure12.1Total liabilities, FY2024, at 2024-03-31$12.1m. XBRL concept ifrs-full:Liabilities. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure0.6Total liabilities, FY2025, at 2025-03-31$594.4k. XBRL concept ifrs-full:Liabilities. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure
Shareholders' equity$m1.7Shareholders' equity, period not labelled, at 2022-03-31$1.7m. XBRL concept ifrs-full:EquityAttributableToOwnersOfParent. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure(0.2)Shareholders' equity, period not labelled, at 2023-03-31−$200.4k. XBRL concept ifrs-full:EquityAttributableToOwnersOfParent. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure(11.0)Shareholders' equity, FY2024, at 2024-03-31−$11.0m. XBRL concept ifrs-full:Equity. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure6.7Shareholders' equity, FY2025, at 2025-03-31$6.7m. XBRL concept ifrs-full:Equity. 20-F filed 2025-06-25, accession 0001213900-25-057893.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.